Format

Send to

Choose Destination
Ther Deliv. 2012 Feb;3(2):195-208.

Nasal-to-CNS drug delivery: where are we now and where are we heading? An industrial perspective.

Author information

1
Pfizer Global Research & Development, Pharmaceutical Sciences-Research Formulations, Eastern Point Road, Groton, CT 06340, USA. margaret.s.landis@pfizer.com

Abstract

Delivery of drug therapeutics across the blood-brain barrier is a challenging task for pharmaceutical scientists. Nasal-to-CNS drug delivery has shown promising results in preclinical efficacy models and investigatory human clinical trials. The further development of this technology with respect to the establishment of valid, predictable preclinical species models, translatable pharmacokinetic-pharmacodynamic relationships and definition of toxicology impact will help attract additional pharmaceutical investment in this drug-delivery approach. Further discoveries in nasal nanotechnology, targeted delivery devices and diagnostic olfactory imaging will serve to fuel the advancements in this area of drug delivery.

PMID:
22834197
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center